文献速递关节外科

比较拉莫司琼与昂丹司琼预防初次全膝关节置换术后鞘内吗啡所致恶心呕吐:一项随机对照试验

Comparison of Ramosetron With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial.
PubMed 文献 · J Arthroplasty · 2016-10-08

该随机对照试验将90例在脊髓麻醉联合鞘内吗啡下接受初次全膝关节置换术的患者术前随机分为昂丹司琼8 mg组或拉莫司琼0.3 mg组,每组45例。拉莫司琼组在术后12-18小时和18-24小时的恶心发生率以及18-24小时的呕吐发生率均显著低于昂丹司琼组,而补救止吐药使用、疼痛评分、患者满意度和药物不良反应两组无显著差异。作者认为术前拉莫司琼较昂丹司琼提供更持久的术后恶心呕吐预防,但需其他试验证实后方可广泛采用。

要点

  • 拉莫司琼组术后12-18小时恶心发生率为3/45,低于昂丹司琼组的11/45(P = .016)。
  • 拉莫司琼组术后18-24小时恶心发生率为1/45,低于昂丹司琼组的9/45(P = .005)。
  • 拉莫司琼组术后18-24小时呕吐发生率为1/45,低于昂丹司琼组的6/45(P = .044)。

核心结论

  • 在本研究条件下,术前给予拉莫司琼较昂丹司琼在全膝关节置换术后提供更持久的术后恶心呕吐预防,且药物不良反应特征相似。
  • 作者指出在拉莫司琼被广泛采用前,需要其他试验证实本研究结果。

研究设计与样本

  • 随机对照试验,患者术前随机接受静脉昂丹司琼8 mg或拉莫司琼0.3 mg。
  • 共90例可评估患者,每组45例。
  • 主要结局为术后恶心呕吐发生率;次要结局为0-6、6-12、12-24和24-48小时的补救止吐药(甲氧氯普胺)需求、疼痛评分、患者满意度和药物不良反应。

主要发现

  • 与昂丹司琼组相比,拉莫司琼组术后12-18小时恶心发生率显著更低:3/45 vs 11/45(P = .016)。
  • 拉莫司琼组术后18-24小时恶心发生率显著低于昂丹司琼组:1/45 vs 9/45(P = .005)。
  • 拉莫司琼组术后18-24小时呕吐发生率显著低于昂丹司琼组:1/45 vs 6/45(P = .044)。
  • 两组在补救止吐药使用、疼痛评分、患者满意度和药物不良反应方面无显著差异。

关键数值与推荐

  • 昂丹司琼剂量为静脉8 mg,拉莫司琼剂量为静脉0.3 mg,均为术前给药。
  • 恶心发生率在12-18小时为拉莫司琼组3/45 vs 昂丹司琼组11/45(P = .016),在18-24小时为1/45 vs 9/45(P = .005)。
  • 呕吐发生率在18-24小时为拉莫司琼组1/45 vs 昂丹司琼组6/45(P = .044)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者指出在拉莫司琼被广泛采用前,需要其他试验证实本研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spinal anesthesia with intrathecal morphine is a reliable, easy to apply, and cost effective method for controlling pain after total knee arthroplasty (TKA). However, postoperative nausea and vomiting (PONV) is a major concern. 5-Hydroxytryptamine receptor 3 (5-HT3) antagonists like ondansetron and ramosetron are commonly used for preventing PONV, but the optimal choice remains unclear. We conducted a study to assess the effectiveness of ramosetron and ondansetron, hypothesizing that the longer acting ramosetron may be better than ondansetron in the first 48 hours after TKA, performed with spinal anesthesia and intrathecal morphine. METHODS: Patients were randomized preoperatively to either intravenous ondansetron (8 mg) or ramosetron (0.3 mg). The primary outcomes were the incidence rates of PONV. Secondary outcomes were the need for a rescue antiemetic (metoclopramide), pain score, patient satisfaction, and adverse drug reactions (ADRs) at 0-6, 6-12, 12-24, and 24-48 hours. RESULTS: Ninety patients were evaluable; 45 patients/arm. Compared with ondansetron, ramosetron was associated with significantly lower incidence rates of nausea at: (1) 12-18 hours: 3/45 vs 11/45 (P = .016), (2) 18-24 hours: 1/45 vs 9/45 (P = .005), and vomiting at 18-24 hours: 1/45 vs 6/45 (P = .044). There were no significant differences in the use of rescue-antiemetic medicine, pain score, patient satisfaction, and ADRs. CONCLUSION: Preoperative ramosetron provided more prolonged PONV prophylaxis than ondansetron after TKA in our setting, and had a similar ADR profile. Other trials are needed to confirm our results before ramosetron is adopted widely.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Pinsornsak P, Teeyaphudit M, Ruetiwarangkoon C, et al. Comparison of Ramosetron With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial. J Arthroplasty. 2016. PMID: 27816366. doi:10.1016/j.arth.2016.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。